Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03638960 · ClinicalTrials.gov registry record · Phase 4
Interscalene Single Shot With Plain Bupivacaine Versus Liposomal Bupivacaine for Arthroscopic Shoulder Surgery
A Phase 4 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT03638960 is a Phase 4 study that has completed, run by University of Southern California. The registered enrollment target is 40 participants.
The verdict
NCT03638960, a Phase 4 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The investigators will be comparing pain scores and opioid use in patients receiving interscalene peripheral blocks with plain bupivacaine versus those receiving liposomal bupivacaine. Liposomal bupivacaine is described as releasing local anesthetic up to 72 hours after its injection; therefore if liposomal bupivacaine can provide extended pain relief compared to plain bupivacaine, the investigators can consider using it as our primary local anesthetic. As secondary outcomes, the investigators will also be looking at difference in functional status and long-term differences between the two local anesthetics.
Interventions
- DRUG Bupivacaine Hydrochloride
- DRUG Bupivacaine liposome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2023-06-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03638960
The ClinicalTrials.gov registry entry for NCT03638960 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine Hydrochloride is the first listed.
NCT03638960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03638960 about?
NCT03638960 is a clinical study titled "Interscalene Single Shot With Plain Bupivacaine Versus Liposomal Bupivacaine for Arthroscopic Shoulder Surgery". The investigators will be comparing pain scores and opioid use in patients receiving interscalene peripheral blocks with plain bupivacaine versus those receiving liposomal bupivacaine. Liposomal bupivacaine is described as releasing local anesthetic up to 72 hours after its injection; therefore if l...
What is the current status of trial NCT03638960?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2019-02-21. Estimated completion is 2023-06-06.
What interventions are being tested in trial NCT03638960?
The interventions under investigation include: Bupivacaine Hydrochloride (DRUG), Bupivacaine liposome (DRUG).
Who is sponsoring clinical trial NCT03638960?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.